Serum cystatin C and the incidence of hypertension in type 1 diabetes mellitus.

Kleins Lab // Publications // Jan 01 2011

PubMed ID: 20885369

Author(s): Sahakyan K, Klein BE, Lee KE, Tsai MY, Klein R. Serum cystatin C and the incidence of hypertension in type 1 diabetes mellitus. Am J Hypertens. 2011 Jan;24(1):59-63. doi: 10.1038/ajh.2010.215. Epub 2010 Sep 30. PMID 20885369

Journal: American Journal Of Hypertension, Volume 24, Issue 1, Jan 2011

BACKGROUND Serum cystatin has been shown to be associated with hypertension in the general population. Little is known on the relationship of serum cystatin C with the long-term hypertension incidence in persons with diabetes. We examined the association of serum cystatin C with the incidence of hypertension over a 15-year period in people with type 1 diabetes mellitus.

METHODS The 15-year cumulative incidence of hypertension was measured in Wisconsin Epidemiologic Study of Diabetic Retinopathy participants. Hypertension was defined as a systolic blood pressure (BP) of ≥140 mm Hg and/or a diastolic BP of ≥90 mm Hg and/or history of use of antihypertensive treatment. The relation of cystatin C and other risk factors to hypertension incidence was determined with generalized linear modeling with the complementary log-log link function.

RESULTS After controlling for age, gender, diabetes duration, body mass index (BMI), glycosylated hemoglobin, and baseline systolic and diastolic BP, the baseline serum cystatin C was associated with the 15-year cumulative incidence of hypertension (hazard ratio (HR) per mg/l of cystatin C: 3.43, and 95% confidence interval: 1.36, 8.63).

CONCLUSIONS These findings show a relationship of serum cystatin C with the incidence of hypertension in type 1 diabetes mellitus. The underlying biological processes remain to be determined.